Best Biotech Companies To Buy For 2016

Best Biotech Companies To Buy For 2016: Prosensa Holding NV (RNA)

Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Companys primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntingtons disease. The Companys clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Companys platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.

DMD is a rare, severe muscle wasting disease that occurs in up to 1 in 3,500 male births. It is commonly diagnosed between the ages of three to five , when boys begin to show signs of impaired motor development. PRO044, the Companys product candidate, addresses a separate sub-population of DMD patients. The Company developed PRO044 using its exon-skipping technology to generate a product candidate with the same mechanism of action that is used by drisapersen.

Advisors' Opinion:

• [By Keith Speights]

  Successful launch
  You couldn't even buy stock in Prosensa (NASDAQ: RNA  ) just a few weeks ago. The biotech launched its IPO on June 28. To say that launch has gone successfully is an understatement. Shares are now more than double the IPO price and climbed 41% this week.

• [By John Udovich]

  Recent news surrounding small cap biotech stocks likeXencor Inc (NASDAQ: XNCR), Prosensa Holding NV (NASDAQ: RNA),Puma Biotechnology Inc (NYSE: PBYI),Geron Corporation (NASDAQ: GERN)
  and TNI BioTech Inc (OTCQB: TNIB) show that while the sector and appetite for bi! otechIPOs may have cooled, lottery tickets can still be found or occur in the sector. Just consider the following recent news or trends:

• [By Sean Williams]

  What: Shares of Prosensa (NASDAQ: RNA  ) , a clinical-stage developer of RNA-modulating therapeutic agents for genetic disorders, jumped as much as 50% after reporting additional clinical findings on drisapersen at the JPMorgan Healthcare Conference.

• [By Leo Sun]

  However, these three biotech stocks -- Amarin (NASDAQ: AMRN  ) , Dendreon (NASDAQ: DNDN  ) , Prosensa (NASDAQ: RNA  ) -- don't fit that category at all. Read on to understand why these dogs of the sector should never be mistaken as underdogs.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/best-biotech-companies-to-buy-for-2016.html